Oral mucositis (OM) associated with cancer treatment not only impairs patients’ quality of life but also causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of Episil® oral liquid, which is an approved protective formulation for the oral mucosa in patients with OM. The extent of the pain-relieving efect, feeling during use, and adverse events or problems were evaluated. | Ueno et al. BMC Cancer 2022 22 90 https s12885-021-09107-6 RESEARCH Open Access Effects of an oral mucosa protective formulation on chemotherapy and or radiotherapy induced oral mucositis a prospective study Takao Ueno1 Wakako Yatsuoka1 Hiroto Ishiki2 Kanako Miyano3 and Yasuhito Uezono3 4 5 Abstract Background Oral mucositis OM associated with cancer treatment not only impairs patients quality of life but also Episil oral liquid which is an approved protective formulation for the oral mucosa in patients with OM. The extent of causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of the pain-relieving effect feeling during use and adverse events or problems were evaluated. Methods In total 10 Japanese cancer patients with OM receiving chemotherapy pretreatment therapy for hemat- opoietic stem cell transplantation or radiation therapy for head and neck cancer were enrolled. mean NRS began to decrease at 5 min after using Episil to p . A significant decrease was Results A numerical rating scale NRS was used to assess oral pain intensity due to OM. Compared to baseline the observed in the pain score after using Episil compared with that before using Episil and this effect lasted up to 120 min. The protective effects of Episil were observed 3 5 min after application. Some patients felt slight soreness or discomfort when applying Episil . However this discomfort due to Episil s stimulation was within the allowable range and transient. No adverse events were observed in any of the cases. Conclusions The results of this prospective study showed that Episil could be an effective treatment to relieve oral pain in Japanese patients with moderate to severe OM and this newly approved product might adequately support patients oral intake. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN-CTR UMIN0 00031 921 . Keywords Bioadhesive .
